Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Cite this paper

@article{Beglinger2012MultipleOS, title={Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.}, author={Christoph Beglinger and Ke Hu and Ying Wang and Emmanuel Bouillaud and Christelle L. S. Darstein and Yanfeng Wang and Pharis Mohideen}, journal={Endocrine}, year={2012}, volume={42 2}, pages={366-74} }